Quantinno Capital Management LP Sells 1,204,481 Shares of Sotera Health Company $SHC

Quantinno Capital Management LP trimmed its position in Sotera Health Company (NASDAQ:SHC) by 85.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 197,372 shares of the company’s stock after selling 1,204,481 shares during the quarter. Quantinno Capital Management LP’s holdings in Sotera Health were worth $2,830,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SHC. Empowered Funds LLC boosted its stake in Sotera Health by 11.1% in the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after acquiring an additional 2,845 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Sotera Health by 14.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after acquiring an additional 43,471 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock valued at $293,000 after acquiring an additional 14,018 shares during the last quarter. Creative Planning lifted its stake in shares of Sotera Health by 15.3% in the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after purchasing an additional 2,673 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Sotera Health by 4.2% in the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after purchasing an additional 12,758 shares during the period. 91.03% of the stock is owned by institutional investors.

Sotera Health Price Performance

SHC opened at $18.86 on Monday. The stock has a market cap of $5.38 billion, a P/E ratio of 33.09 and a beta of 1.77. Sotera Health Company has a 12 month low of $12.94 and a 12 month high of $19.85. The company has a quick ratio of 2.55, a current ratio of 2.80 and a debt-to-equity ratio of 3.33. The company has a fifty day simple moving average of $17.13 and a 200 day simple moving average of $16.31.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The firm had revenue of $321.38 million for the quarter, compared to analyst estimates of $309.70 million. During the same period in the previous year, the company posted $0.20 earnings per share. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, research analysts expect that Sotera Health Company will post 0.87 EPS for the current year.

Insider Buying and Selling at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.36% of the stock is owned by company insiders.

Trending Headlines about Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of Sotera Health in a research note on Friday. UBS Group set a $19.00 target price on Sotera Health in a research note on Wednesday, June 24th. The Goldman Sachs Group began coverage on Sotera Health in a report on Friday, June 5th. They set a “buy” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Citigroup increased their price target on shares of Sotera Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.50.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.